Topic: vaccine development
While Valneva already markets two vaccines, the company is open to building its commercial business through small acquisitions, its CEO said.
Here is some other vaccine news of note for the week.
To make sense of Sanofi's Dengvaxia experiences, look no further than the old adage: Learn from your mistakes.
ImmusanT hopes Nexvax2 can help desensitize T cells responsible for autoimmune response in celiac disease.
The FDA fast-tracked Valneva's shot against chikungunya, a disease with no approved vaccines.
Since GSK pulled LYMErix in 2002, there's been no FDA-approved Lyme shot, and Valneva's VLA15 is the only active clinical program.
Experts urged the U.S. to allow CDC staff to return to the field, though WHO's director-general insists financial and other support should suffice.
With the help of BioNTech and CEPI's $8.4 million, Imperial College London will work on a self-amplifying RNA vaccine platform.
As officials scramble to contain an Ebola outbreak in the Democratic Republic of Congo, the WHO is worried that Merck's vaccine stockpile won't last.
Based in Oxford and slated to open in 2022, the center will focus on creating rapid, cost-effective ways of developing and manufacturing vaccines.